Improvement of bone marrow fibrosis with ruxolitinib: Will this finding change our perception of the drug?

Expert Review of Hematology

Volumn 8, Issue 4, 2015, Pages 387-389

  Breccia, Massimo ^a   Molica, Matteo ^a   Colafigli, Gioia ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

fibrosis; myelofibrosis; ruxolitinib

Indexed keywords

CALMODULIN; INTERLEUKIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RUXOLITINIB; SERUM AMYLOID P; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; JANUS KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ABDOMINAL DISCOMFORT; AGED; ANGIOGENESIS; CASE REPORT; CLINICAL EXAMINATION; DISEASE COURSE; DRUG DOSE REDUCTION; ENDOTHELIUM CELL; FOLLOW UP; HEMATOPOIETIC CELL; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MACROPHAGE; MALE; MAST CELL; MEGAKARYOCYTE; MICROENVIRONMENT; MYELOFIBROSIS; NIGHT SWEAT; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; ANTAGONISTS AND INHIBITORS; METABOLISM; PRIMARY MYELOFIBROSIS;

HUMANS; JANUS KINASES; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; TREATMENT OUTCOME;

EID: 84936939904     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2015.1041494     Document Type: Review

References (13)

1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807
2. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013;122:4047-53
3. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica 2013;98: abstract 591
4. Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013;98:1872-6
5. Molica M, Serrao A, Saracino R, et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? Ann Hematol 2014;93:1951-2
6. Al-Ali HK, Hubert K, Lange T, et al. Complete clinical, histopathologic and molecular remission of primary myelofibrosis with long-term treatment with the JAK1/2 inhibitor ruxolitinib. Blood 2014;124:abstract 1836
7. McLornan DP, Mead AJ, Jackson G, Harrison CN. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 2012;157:413-25
8. Silver RT, Vandris K, Goldman JJ. Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011;117: 6669-72
9. Iannotto JC, Boyer-Perrard F, Gyan E, et al. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013;162:783-91
10. Le Bousse Kerdiles MC, Martyrè MC, Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008;19:69-80
11. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Changes in activated bone marrow macrophages and mast cells in patients with myelofibrosis following ruxolitinib therapy. Blood 2014;124:abstract 3184
12. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib therapy effectively modulates CD34+ hematopoietic progenitors and bone marrow angiogenesis in patients with myelofibrosis. Blood 2014;124:abstract 4578
13. Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib-induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels. Blood 2014;124:abstract 3182